Cidara Therapeutics Announces Presentation Of Data From Its Antifungal Drug Development Programs At ECCMID 2016

SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies of its novel echinocandin, CD101, will be presented at the 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, April 9-12, 2016. Specifically, Cidara’s presentations will feature results from the successful Phase 1 dose-escalation study of CD101 IV as well as provide an update on the company’s anti-infective product pipeline, including key clinical and regulatory milestones for CD101 and the CloudbreakTM immunotherapy platform.

Back to news